We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App





LumiraDx Presents Its Innovative, Next Generation Point of Care Diagnostics Platform at MEDICA 2021

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: LumiraDx at MEDICA 2021 (Photo courtesy of LumiraDx)
Image: LumiraDx at MEDICA 2021 (Photo courtesy of LumiraDx)

LumiraDx (London, UK) presented its innovative, next generation point of care diagnostics platform and seamless digital connectivity at this year’s MEDICA, the world’s largest medical trade fair, held from 15-18 November in Düsseldorf, Germany. For more than 40 years it has welcomed several thousand exhibitors from more than 50 countries. The exhibition covered all aspects of medicine and clinical care; from electromedical equipment and medical technology, physiotherapy and orthopedic technology to laboratory equipment and diagnostics.

At MEDICA 2021, LumiraDx presented the LumiraDx Platform, its innovative, disruptive solution designed to deliver lab-comparable performance to transform community care. The LumiraDx Platform is an innovative, next generation point of care diagnostic system that combines a small, portable instrument, advanced low cost test strip and seamless secure digital connectivity to the Cloud and hospital IT systems. The LumiraDx Platform and tests are designed on the same principles as lab analyzer systems, to deliver accurate results compared to laboratory reference assays across a number of parameters, in a portable, easy-to-use point of care solution. Easy and intuitive to use, it requires only basic training and is designed to be affordable and accessible at the point of care.

LumiraDx offers a broad menu of lab comparable results on the LumiraDx Platform that aims to transform community care. It has developed SARS-CoV-2 antigen and antibody tests that provide lab comparable results for COVID-19 testing in minutes on a single platform. The LumiraDx Platform menu also includes point of care tests for INR and D-Dimer with high levels of accuracy comparable to central lab-based tests. The company has a pipeline of more than 30 assays, initially focused on some of the most common conditions being diagnosed or managed with POC testing such as coagulation disorders, infectious diseases, cardiovascular and diabetes.

Related Links:
LumiraDx 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Automatic ELISA Workstation
URANUS AE65

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.